Puma Biotechnology earnings were $30.3M for the trailing 12 months ending Dec 31, 2024, with 34.8% growth year over year. The latest PBYI earnings report on Dec 31, 2024 announced Q4 2024 earnings of $19.3M, down 5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PBYI reported annual earnings of $30.3M, with 40.2% growth.
PBYI past earnings growth
How has PBYI's earnings growth performed historically?
What were Puma Biotechnology's earnings last quarter?
On PBYI's earnings call on Invalid Date, Puma Biotechnology (NASDAQ: PBYI) reported Q4 2024 earnings per share (EPS) of $0.39, up 50% year over year. Total PBYI earnings for the quarter were $19.31 million. In the same quarter last year, Puma Biotechnology's earnings per share (EPS) was $0.26.
As of the last Puma Biotechnology earnings report, Puma Biotechnology is currently profitable. Puma Biotechnology's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $30.28 million, a 40.23% increase year over year.
What was PBYI's earnings growth in the past year?
As of Puma Biotechnology's earnings date in Invalid Date, Puma Biotechnology's earnings has grown 34.78% year over year. This is 22.78 percentage points higher than the US Biotechnology industry earnings growth rate of 12%. PBYI earnings in the past year totalled $30.28 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.